Want to see ANNX full AI Analyst Report?
ANNX Stock Chart & Stats
$6.54
-$0.26(-5.25%)
At close: 4:00 PM EST
$6.54
-$0.26(-5.25%)
Day’s Range― - ―
52-Week Range$2.03 - $7.18
Previous CloseN/A
Volume252.73K
Average Volume (3M)4.58M
Market Cap
$950.29M
Enterprise Value$876.28
Total Cash (Recent Filing)$225.03M
Total Debt (Recent Filing)$25.43M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 17, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding163,842,540
10 Day Avg. Volume5,615,369
30 Day Avg. Volume4,582,164
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)3.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.20Price Target Upside147.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused C1q-targeted PipelineAnnexon’s concentrated R&D focus on inhibiting C1q creates a clear scientific platform addressing complement-mediated damage across multiple indications. This mechanism-based specialization can produce durable competitive differentiation, enable pipeline expansion, and attract partnerships if clinical proof emerges.
Low Financial Leverage And Equity CushionRelatively low leverage and a meaningful equity base provide financial flexibility uncommon for smaller clinical-stage biotechs. This reduces immediate solvency pressure, supports ongoing R&D spend, and gives management time to advance programs or negotiate partnerships without urgent debt servicing constraints.
Advancing Pivotal Program Toward Phase 3 ReadoutClinical evidence and an upcoming Phase 3 ARCHER II topline create a durable program-level catalyst. A successful pivotal readout could validate the technology, unlock regulatory pathways, enable commercialization or partner deals, and materially change the company’s long-term revenue prospects.
Bears Say
Pre-revenue With Large Recurring LossesAbsence of product revenue combined with substantial, persistent net losses means the company must rely on external funding to sustain operations. Over time this pressures capital strategy, increases dilution risk, and constrains long-term planning unless a partner or successful regulatory outcome emerges.
Accelerating Cash BurnSharply negative and worsening operating and free cash flow shortens runway and elevates the likelihood of near-term financings. Structural acceleration in burn forces management to prioritize capital raises or partnerships, which can disrupt clinical timelines and increase execution risk over the next several quarters.
Expanded Share Authorization Increases Dilution RiskBoard-approved expansion of authorized shares provides flexibility to raise capital via equity issuance. While useful strategically, it materially increases the potential for shareholder dilution in future financings or licensing transactions, affecting existing ownership and long-term shareholder value.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences, Inc.’s price range in the past 12 months?
Annexon Biosciences, Inc. lowest stock price was $2.03 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences, Inc.’s market cap?
Annexon Biosciences, Inc.’s market cap is $950.29M.
When is Annexon Biosciences, Inc.’s upcoming earnings report date?
Annexon Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were Annexon Biosciences, Inc.’s earnings last quarter?
Annexon Biosciences, Inc. released its earnings results on May 07, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.053.
Is Annexon Biosciences, Inc. overvalued?
According to Wall Street analysts Annexon Biosciences, Inc.’s price is currently Undervalued.
Does Annexon Biosciences, Inc. pay dividends?
Annexon Biosciences, Inc. does not currently pay dividends.
What is Annexon Biosciences, Inc.’s EPS estimate?
Annexon Biosciences, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Annexon Biosciences, Inc. have?
Annexon Biosciences, Inc. has 163,842,540 shares outstanding.
What happened to Annexon Biosciences, Inc.’s price movement after its last earnings report?
Annexon Biosciences, Inc. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 3.08%.
Which hedge fund is a major shareholder of Annexon Biosciences, Inc.?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.20 (147.71% Upside)
$16.20 (147.71% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
147.86%
12-Months-Change
Fundamentals
Return on Equity
-101.19%
Trailing 12-Months
Asset Growth
-13.25%
Trailing 12-Months
Company Description
Annexon Biosciences, Inc.
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
ANNX Stock 12 Month Forecast
Average Price Target
$16.20
▲(147.71% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
7.11% Insiders
18.73% Mutual Funds
0.32% Other Institutional Investors
57.57% Public Companies and
Individual Investors